Rongzhen Xu

3.3k total citations
87 papers, 2.5k citations indexed

About

Rongzhen Xu is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Rongzhen Xu has authored 87 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Molecular Biology, 20 papers in Hematology and 15 papers in Oncology. Recurrent topics in Rongzhen Xu's work include Chronic Myeloid Leukemia Treatments (11 papers), Berberine and alkaloids research (10 papers) and Acute Myeloid Leukemia Research (9 papers). Rongzhen Xu is often cited by papers focused on Chronic Myeloid Leukemia Treatments (11 papers), Berberine and alkaloids research (10 papers) and Acute Myeloid Leukemia Research (9 papers). Rongzhen Xu collaborates with scholars based in China, United States and Hong Kong. Rongzhen Xu's co-authors include Xiao-Fang Yu, Shu Zheng, Zhiwen He, Gongying Chen, Wendong Huang, Xuzhao Zhang, Tao Wang, Hong Zhou, Xiaoxian Gan and Zhipeng Meng and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Blood.

In The Last Decade

Rongzhen Xu

85 papers receiving 2.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rongzhen Xu China 28 1.2k 460 449 446 424 87 2.5k
Jeng‐Pyng Shaw United States 18 1.1k 0.9× 224 0.5× 538 1.2× 516 1.2× 292 0.7× 29 2.2k
Chiang J. Li United States 21 1.7k 1.4× 448 1.0× 122 0.3× 439 1.0× 230 0.5× 42 2.8k
Maurizio Cianfriglia Italy 29 1.3k 1.0× 215 0.5× 395 0.9× 340 0.8× 140 0.3× 100 2.5k
Moon Kyoo Jang United States 28 3.1k 2.6× 368 0.8× 187 0.4× 617 1.4× 359 0.8× 65 4.5k
Mara Cirone Italy 36 1.5k 1.2× 125 0.3× 174 0.4× 684 1.5× 1.4k 3.3× 144 3.5k
Bing Tian United States 36 2.1k 1.7× 75 0.2× 274 0.6× 1.1k 2.6× 670 1.6× 74 3.9k
Subrata Sinha India 25 1.3k 1.1× 75 0.2× 224 0.5× 294 0.7× 293 0.7× 159 2.4k
Maria Rosaria Ruocco Italy 25 886 0.7× 283 0.6× 106 0.2× 472 1.1× 163 0.4× 51 1.8k
Hongxia Fan China 24 977 0.8× 79 0.2× 453 1.0× 254 0.6× 624 1.5× 59 2.0k
Richard C. Najarian United States 15 1.4k 1.1× 79 0.2× 316 0.7× 474 1.1× 707 1.7× 16 3.1k

Countries citing papers authored by Rongzhen Xu

Since Specialization
Citations

This map shows the geographic impact of Rongzhen Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rongzhen Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rongzhen Xu more than expected).

Fields of papers citing papers by Rongzhen Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rongzhen Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rongzhen Xu. The network helps show where Rongzhen Xu may publish in the future.

Co-authorship network of co-authors of Rongzhen Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Rongzhen Xu. A scholar is included among the top collaborators of Rongzhen Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rongzhen Xu. Rongzhen Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Mengyuan, Shuwen Zheng, Wen Lei, et al.. (2025). HERV‐K TM Subunit Elicits CD8 + T Cell Anergy and Tumor Immune Evasion via Targeting CD3 Coreceptor ε in AML and PDAC. Advanced Science. 13(1). e17432–e17432.
2.
Li, Fenglin, et al.. (2024). G Protein-Coupled Receptor 183 Mediates Homoharringtonine Resistance Via NF-Κb Pathway in Acute Myeloid Leukemia. Blood. 144(Supplement 1). 5793–5793. 1 indexed citations
3.
Zhang, Lei, Xin He, Yun Liang, et al.. (2018). Novel synthetic 4-chlorobenzoyl berbamine inhibits c-Myc expression and induces apoptosis of diffuse large B cell lymphoma cells. Annals of Hematology. 97(12). 2353–2362. 7 indexed citations
4.
Shao, Shiqun, Quan Zhou, Jingxing Si, et al.. (2017). A non-cytotoxic dendrimer with innate and potent anticancer and anti-metastatic activities. Nature Biomedical Engineering. 1(9). 745–757. 89 indexed citations
5.
Meng, Zhipeng, Tao Li, Xiaoxiao Ma, et al.. (2013). Berbamine Inhibits the Growth of Liver Cancer Cells and Cancer-Initiating Cells by Targeting Ca2+/Calmodulin-Dependent Protein Kinase II. Molecular Cancer Therapeutics. 12(10). 2067–2077. 72 indexed citations
6.
Meng, Zhipeng, Xiaoqiong Wang, Yichao Gan, et al.. (2012). Deletion of IFNγ enhances hepatocarcinogenesis in FXR knockout mice. Journal of Hepatology. 57(5). 1004–1012. 25 indexed citations
7.
Liang, Yun, et al.. (2011). Berbamine inhibits proliferation and induces apoptosis of KU812 cells by increasing Smad3 activity. Journal of Zhejiang University SCIENCE B. 12(7). 568–574. 23 indexed citations
8.
Shang, Hong, Ping Zhong, Jing Liu, et al.. (2010). High Prevalence and Genetic Diversity of HCV among HIV-1 Infected People from Various High-Risk Groups in China. PLoS ONE. 5(5). e10631–e10631. 30 indexed citations
9.
Kong, Minjian, et al.. (2010). Effects of polyphyllin I on growth inhibition of human non-small lung cancer cells and in xenograft. Acta Biochimica et Biophysica Sinica. 42(11). 827–833. 53 indexed citations
10.
Liang, Yun, et al.. (2009). [Berbamine induces apoptosis of multiple myeloma RPMI 8226 cells by activating GADD45/JNK pathway].. PubMed. 38(5). 439–44. 4 indexed citations
11.
Liang, Qiaoyi, Jiayi Ding, Rongzhen Xu, Zefeng Xu, & Shu Zheng. (2009). Identification of a novel human endogenous retrovirus and promoter activity of its 5′ U3. Biochemical and Biophysical Research Communications. 382(2). 468–472. 15 indexed citations
12.
Ma, Ting, Ying Gu, Xuzhao Zhang, et al.. (2009). Berbamine derivatives: A novel class of compounds for anti-leukemia activity. European Journal of Medicinal Chemistry. 44(8). 3293–3298. 46 indexed citations
13.
Zhang, Wei, Xuzhao Zhang, Chunjuan Tian, et al.. (2007). Cytidine deaminase APOBEC3B interacts with heterogeneous nuclear ribonucleoprotein K and suppresses hepatitis B virus expression. Cellular Microbiology. 0(0). 2993328737–???. 59 indexed citations
14.
15.
Wang, Guanyu, et al.. (2007). Berbamine induces apoptosis in human hepatoma cell line SMMC7721 by loss in mitochondrial transmembrane potential and caspase activation. Journal of Zhejiang University SCIENCE B. 8(4). 248–255. 37 indexed citations
16.
Ying, Songcheng, Xuzhao Zhang, Phuong Thi Nguyen Sarkis, Rongzhen Xu, & Xiao‐Fang Yu. (2007). Cell-specific Regulation of APOBEC3F by Interferons. Acta Biochimica et Biophysica Sinica. 39(4). 297–304. 25 indexed citations
17.
Xu, Rongzhen. (2007). Shp2, a novel oncogenic tyrosine phosphatase and potential therapeutic target for human leukemia. Cell Research. 17(4). 295–297. 14 indexed citations
18.
Tian, Chunjuan, Xianghui Yu, Wei Zhang, et al.. (2006). Differential Requirement for Conserved Tryptophans in Human Immunodeficiency Virus Type 1 Vif for the Selective Suppression of APOBEC3G and APOBEC3F. Journal of Virology. 80(6). 3112–3115. 112 indexed citations
19.
Sarkis, Phuong Thi Nguyen, Songcheng Ying, Rongzhen Xu, & Xiao-Fang Yu. (2006). STAT1-Independent Cell Type-Specific Regulation of Antiviral APOBEC3G by IFN-α. The Journal of Immunology. 177(7). 4530–4540. 83 indexed citations
20.
Xu, Rongzhen, Qinghua Dong, Xiaoying Zhao, et al.. (2005). Berbamine: A novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity. Leukemia Research. 30(1). 17–23. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jeng‐Pyng Shaw Breakdown of academic impact, for papers by Chiang J. Li Breakdown of academic impact, for papers by Maurizio Cianfriglia Breakdown of academic impact, for papers by Moon Kyoo Jang Breakdown of academic impact, for papers by Mara Cirone Breakdown of academic impact, for papers by Bing Tian Breakdown of academic impact, for papers by Subrata Sinha Breakdown of academic impact, for papers by Maria Rosaria Ruocco Breakdown of academic impact, for papers by Hongxia Fan Breakdown of academic impact, for papers by Richard C. Najarian
Rankless by CCL
2026